

April 29, 2020

**Important Update to Previous Announcement**

**Pfizer Announces Additional Payment-Terms Adjustments for Prevnar 13<sup>®</sup>  
(Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM<sub>197</sub> Protein])  
and Trumenba<sup>®</sup> (Meningococcal Group B Vaccine)  
Effective April 29, 2020 – August 31, 2020**

Dear Healthcare Provider,

Pfizer recognizes that we are all living through a major health crisis and understands that there continue to be shifting needs for healthcare systems, healthcare providers and patients. As an update to the continuing coronavirus disease 2019 (COVID-19) pandemic and recent discussions with the American Academy of Pediatrics (AAP), I am writing to provide an update to the temporary payment-terms extension for Prevnar 13<sup>®</sup> (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM<sub>197</sub> Protein]) and Trumenba<sup>®</sup> (Meningococcal Group B Vaccine) originally communicated on March 26, 2020.

Effective April 29 2020, all open invoices dated January 1, 2020 or later for Pfizer vaccines purchased through [primevaccines.pfizer.com](http://primevaccines.pfizer.com) or through Pfizer Customer Service for physicians, clinics, and group practices will have invoice payment due dates automatically extended to August 31, 2020 or receive 75-day payment terms, whichever is later. No action is required on your part. No new invoices will be issued; therefore, we recommend you simply make note of the updated payment due date on your current invoice. This change also applies to all NEW orders for these customers placed directly through Pfizer between today and August 31, 2020. The 2% prompt-pay discount will continue to apply to payments made within these terms. Please keep in mind that this extension in payment terms on past invoices could result in multiple invoices coming due at the same.

These temporary payment terms will apply to any new vaccine orders placed either online at [primevaccines.pfizer.com](http://primevaccines.pfizer.com) or via Pfizer Customer Service at 1-800-666-7248 through August 31, 2020.

**Temporary Payment Terms - Effective April 29, 2020 through August 31, 2020**

Vaccine	Temporary Payment Terms	Payment Terms After August 31, 2020
Prevnar 13 <sup>®</sup>	2% through August 31, 2020, Net September 1, 2020 OR 2% 75 days, Net 76 days, whichever is later	2% 75 days, Net 76 days
Trumenba <sup>®</sup>	2% through August 31, 2020, Net September 1, 2020 OR 2% 75 days, Net 76 days, whichever is later	2% 75 days, Net 76 days

Pfizer recently announced updates on key advances in our commitment to protect humankind from this escalating pandemic and prepare the industry to better respond to future global health crises. As outlined in our five-point plan to combat the global COVID-19 pandemic, the company has been collaborating across the healthcare innovation ecosystem ranging from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis.

As we highlighted in our last update, our manufacturing and supply chain professionals have been working nonstop to ensure that the supply of Pfizer medicines continue to be available to patients. Currently, we do not anticipate any COVID-19 related shortages of our vaccines in the United States.

During these unprecedented times, we understand your needs may have evolved because of fewer patients visiting physician offices for routine well-visit appointments. Therefore, again, we are asking our customers to only order product quantities needed to support patient needs at this time.

We encourage you to contact your Pfizer Vaccines Territory Manager with any questions you may have. Alternatively, please feel free to contact Pfizer Customer Service at 1-800-666-7248 for additional assistance.

Sincerely,



David Hering  
Regional President Vaccines North America  
Pfizer Inc.